CR 3465

Drug Profile

CR 3465

Alternative Names: Leukotriene CYS-LT1 - Rottapharm; Leukotriene LTD4 antagonists - Rottapharm

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Rottapharm
  • Developer Rottapharm Madaus
  • Class Aromatic amino acids; Small molecules
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Interstitial cystitis

Most Recent Events

  • 23 Oct 2014 CR 3465 is still in phase I trials for Asthma and Interstitial cystitis in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
  • 24 Feb 2010 Phase-I clinical trials in Asthma in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top